The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
The history of dopamine and levodopa in the treatment of Parkinson's disease: Dopamine and Levodopa in the Treatment of PD
Abstract
The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder. This review describes these events and the persons who carried out these accomplishments. Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagatsu, T., Levitt, M., & Udenfriend, S. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93832-9 · Cited by 2,058
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
DOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Demonstration and mapping out of nigro-neostriatal dopamine neurons
Andén, N.-E., Carlsson, A., Dahlström, A., Fuxe, K., Hillarp, N.-Å., & Larsson, K. (1964) · Life Sciences · doi:10.1016/0024-3205(64)90161-4 · Cited by 813
Chemical structure and sympathomimetic action of amines
Barger, G., & Dale, H. H. (1910) · The Journal of Physiology · doi:10.1113/jphysiol.1910.sp001392 · Cited by 726
THE OCCURRENCE, DISTRIBUTION AND PHYSIOLOGICAL ROLE OF CATECHOLAMINES IN THE NERVOUS SYSTEM
Carlsson, A. (1959) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07428-9 · Cited by 689
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
Marsden, C. D., & Parkes, J. D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91416-1 · Cited by 661
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
On the Presence of 3-Hydroxytyramine in Brain
CARLSSON, A., LINDQVIST, M., MAGNUSSON, T., & WALDECK, B. (1958) · Science · doi:10.1126/science.127.3296.471 · Cited by 634
Treatment of Parkinsonism With Levodopa
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 604
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].
Birkmayer, W., & Hornykiewicz, O. (1961) · PubMed · Cited by 541
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H., Hars, V., & Marton, J. (1985) · Journal of Neural Transmission · doi:10.1007/bf01245973 · Cited by 436
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11869 · Cited by 407
INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM
POIRIER, L. J., & SOURKES, T. L. (1965) · Brain · doi:10.1093/brain/88.1.181 · Cited by 339
Serotonin Release as a Possible Mechanism of Reserpine Action
Pletscher, A., Shore, P. A., & Brodie, B. B. (1955) · Science · doi:10.1126/science.122.3165.374 · Cited by 336
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Occurrence and distribution of catechol amines in brain.
Bertler, Å., & Rosengren, E. (1959) · PubMed · Cited by 322
Striatal inhomogeneities and basal ganglia function
Penney, J. B., & Young, A. B. (1986) · Movement Disorders · doi:10.1002/mds.870010102 · Cited by 321
Biochemistry and pharmacology of the basal ganglia
Yahr, M. D. (1965) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(65)90018-3 · Cited by 294
Crossman, A. R. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90322-8 · Cited by 282
Selegiline slows the progression of the symptoms of Parkinson disease
Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., & the Swedish Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000204007.46190.54 · Cited by 271
Distribution of catechol compounds in human brain
Sano, I., Gamo, T., Kakimoto, Y., Taniguchi, K., Takesada, M., & Nishinuma, K. (1959) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(59)90652-3 · Cited by 263
Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Self-citationFAHN, S. (1974) · Neurology · doi:10.1212/wnl.24.5.431 · Cited by 230
Self-citationCatechol Compounds in Rat Tissues and in Brains of Different Animals
MONTAGU, K. A. (1957) · Nature · doi:10.1038/180244a0 · Cited by 206
Kurth, M. C., Adler, C. H., St. Hilaire, M., Singer, C., Waters, C., LeWitt, P., Chernik, D. A., Dorflinger, E. E., & Yoo, K. (1997) · Neurology · doi:10.1212/wnl.48.1.81 · Cited by 205
Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa)
MCDOWELL, F., LEE, J. E., SWIFT, T., SWEET, R. D., OGSBURY, J. S., & KESSLER, J. T. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-1-29 · Cited by 183
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Cohen, G. (1987) · PubMed · Cited by 173
L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent
Hornykiewicz, O. (2002) · Amino Acids · doi:10.1007/s00726-001-0111-9 · Cited by 168
Linkage mapping of dopa–responsive dystonia (DRD) to chromosome 14q
Nygaard, T. G., Wilhelmsen, K. C., Risch, N. J., Brown, D. L., Trugman, J. M., Conrad Gilliam, T., Fahn, S., & Weeks, D. E. (1993) · Nature Genetics · doi:10.1038/ng1293-386 · Cited by 164
Self-citationPatterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
Muenter, M. D., Sharpless, N. S., Tyce, G. M., & Darley, F. L. (1977) · PubMed · Cited by 151
Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba.
Guggenheim, M. (1913) · Hoppe-Seyler´s Zeitschrift für physiologische Chemie · doi:10.1515/bchm2.1913.88.4.276 · Cited by 149
Ruottinen, H., & Rinne, U. K. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.1.36 · Cited by 145
Ruottinen, H., & Rinne, U. K. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619040-00001 · Cited by 127
Degkwitz, R., Frowein, R. A., Kulenkampff, C., & Mohs, U. (1960) · Journal of Molecular Medicine · doi:10.1007/bf02189076 · Cited by 126
Dopamine miracle: From brain homogenate to dopamine replacement
Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10115 · Cited by 122
Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor
Papavasiliou, P. S., Cotzias, G. C., Düby, S., Steck, A. J., Fehling, C., & Bell, M. A. (1972) · New England Journal of Medicine · doi:10.1056/nejm197201062860102 · Cited by 121
Kaakkola, S., Teräväinen, H., Ahtila, S., et al. (1994) · Neurology · doi:10.1212/wnl.44.1.77 · Cited by 115
Roberts, J. W., Cora‐Locatelli, G., Bravi, D., et al. (1993) · Neurology · doi:10.1212/wnl.43.12.2685 · Cited by 107
Early-Morning Dystonia: A Late Side Effect of Long-term Levodopa Therapy in Parkinson's Disease
Melamed, E. (1979) · Archives of Neurology · doi:10.1001/archneur.1979.00500410086014 · Cited by 106
Klawans, H. L., Goetz, C. G., & Bergen, D. C. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490470075011 · Cited by 103
Molecular Genetics of Dopa-Responsive Dystonia
Ichinose, H., Suzuki, T., Inagaki, H., Ohye, T., & Nagatsu, T. (1999) · Biological Chemistry · doi:10.1515/bc.1999.175 · Cited by 101
Merello, M., Lees, A. J., Webster, R. A., Bovingdon, M., & Gordin, A. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.2.186 · Cited by 98
Episodic unresponsiveness to single doses of L‐dopa in parkinsonian fluctuators
Melamed, E., Bitton, V., & Zelig, O. (1986) · Neurology · doi:10.1212/wnl.36.1.100 · Cited by 91
Considerations in the management of parkinsonism
Fahn, S., & Calne, D. B. (1978) · Neurology · doi:10.1212/wnl.28.1.5 · Cited by 88
Self-citationTREATMENT OF PARKINSON'S SYNDROME WITH L-DOPA A DOUBLE BLIND STUDY
Fehling, C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1966.tb01188.x · Cited by 77
The contribution of basal ganglia to limb control
DeLong, M. R., Alexander, G. E., Mitchell, S. J., & Richardson, R. T. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)63411-1 · Cited by 72
Poewe, W., Lees, A. J., & Stern, G. M. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198610000-00003 · Cited by 62
Clinical and biochemical studies with controlled‐release levodopa/carbidopa
Nutt, J. G., Woodward, W. R., & Carter, J. H. (1986) · Neurology · doi:10.1212/wnl.36.9.1206 · Cited by 60
Dopamine metabolism in Parkinson's disease
Greer, M., & Williams, C. M. (1963) · Neurology · doi:10.1212/wnl.13.1.73 · Cited by 58
Autopsy findings in parkinsonism following treatment with levodopa
Yahr, M. D., Wolf, A., Antunes, J. L. F., Miyoshi, K., & Duffy, P. E. (1972) · Neurology · doi:10.1212/wnl.22.5_part_2.56 · Cited by 56
Lees, A. J. (2008) · European Neurology · doi:10.1159/000116207 · Cited by 51
Dihydroxyphenylalanine in Extrapyramidal Disease
Friedhoff, A. J., HEKIMIAN, L., ALPERT, M., & TOBACH, E. (1963) · JAMA · doi:10.1001/jama.1963.73700170010010c · Cited by 49
Parkinson's disease and motor fluctuations: Long‐acting carbidopa/levodopa (CR‐4‐Sinemet)
Goetz, C. G., Tanner, C. M., Klawans, H. L., Shannon, K. M., & Carroll, V. S. (1987) · Neurology · doi:10.1212/wnl.37.5.875 · Cited by 47
Lees, A. J., Shaw, K. M., & Stern, G. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92939-7 · Cited by 47
Davis, T. L., Roznoski, M., & Burns, R. S. (1995) · Movement Disorders · doi:10.1002/mds.870100321 · Cited by 38
The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
Rd, S., & MCDOWELL, F. H. (1974) · PubMed · Cited by 38
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton, J. T., Morris, J. L., Bush, D., Smith, M., Liss, C. L., & Reines, S. A. (1989) · PubMed · Cited by 36
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Juncos, J. L., Fabbrini, G., Mouradian, M. M., & Chase, T. N. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520220016008 · Cited by 29
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Hutton, J. T., & Morris, J. L. (1992) · PubMed · Cited by 27
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos, J. L., Fabbrini, G., Mouradian, M. M., et al. (1987) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.50.2.194 · Cited by 27
Newer Medical Treatments in Parkinsonism
SCHWARZ, G. A., & Fahn, S. (1970) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)32643-8 · Cited by 26
Self-citationSage, J. I., & Mark, M. H. (1988) · Clinical Neuropharmacology · doi:10.1097/00002826-198804000-00009 · Cited by 25
Variations in the "on-off" effect.
Yahr, M. D. (1974) · PubMed · Cited by 24
Mitchell, R. J., Earl, L., Bisucci, T., et al. (1994) · Human Heredity · doi:10.1159/000154195 · Cited by 22
Cited by
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease
Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S., Bergman, H., Agid, Y., DeLong, M. R., & Obeso, J. A. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2915 · Cited by 1,134
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
García-Sánchez, A., Miranda-Díaz, A. G., & Cardona-Muñoz, E. G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2082145 · Cited by 331
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
Samaco, R. C., Mandel-Brehm, C., Chao, H.-T., Ward, C. S., Fyffe-Maricich, S. L., Ren, J., Hyland, K., Thaller, C., Maricich, S. M., Humphreys, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912257106 · Cited by 257
Metadata
- Authors
- Fahn, S.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2008
- Volume
- 23
- Issue
- S3
- Pages
- S497-S508
- ISSN
- 0885-3185 (ISSN-L)
- OpenAlex
- W2070914201
- Cited by
- 339
- References
- 74
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.